Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2026-01-29 @ 3:51 AM
Study NCT ID:
NCT04920968
Status:
RECRUITING
Last Update Posted:
2025-04-24
First Post:
2021-04-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Sponsor:
Maria Sklodowska-Curie National Research Institute of Oncology
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | CD20-positive Acute Lymphoblastic Leukemia | View |
Keywords: